Russell Investments Group
AGRX

Russell Investments Group’s Agile Therapeutics AGRX Stock Holding History

Russell Investments Group’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-76
Closed -$393K – 2986
2018
Q1 		$393K Sell
76
-71
-48% -$469K ﹤0.01% 2533
2017
Q4 		$811K Buy
147
+41
+39% +$382K ﹤0.01% 2244
2017
Q3 		$943K Buy
+106
New +$814K ﹤0.01% 2170

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group's AGRX Position: Q2 2018 in Review

Russell Investments Group sold out of Agile Therapeutics (AGRX) in Q2 2018, closing a stake of 76 shares — an estimated $393K sold.

Russell Investments Group first reported a position in AGRX in Q3 2017 and held it in 3 quarters. The position peaked at $943K in Q3 2017. 38 funds tracked by Wall St. Rank hold AGRX as of Q2 2018.

  • Russell Investments Group reported no remaining Agile Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Russell Investments Group sold 76 Agile Therapeutics shares in Q2 2018, an estimated $393K.
  • Russell Investments Group first reported a position in Agile Therapeutics in Q3 2017 and held it in 3 quarters.
  • Russell Investments Group's Agile Therapeutics position peaked at $943K in Q3 2017.
  • 38 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2018.

Based on Russell Investments Group's 13F filing for Q2 2018, filed 8 Aug 2018.